REGENERON PHARMACEUTICALS, INC.

REGN · CIK 0000872589

18 fiscal years · 65 SEC filings · every number carries its receipt

Revenue (FY)

$14.34B1.0%

FY2025

Net income (FY)

$4.50B2.1%

FY2025

Free cash flow (FY)

$4.08B11.3%

FY2025

Diluted EPS (FY)

$41.488.2%

FY2025

The story, charted

The shape of the business

FY2008–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 60.1× since FY2008 · net margin -33.2% → 31.4%

MarginsNet marginFCF margin

FY2025: net 31.4% · free cash flow 28.4% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $4.98B operating cash − $898.4M capex = $4.08B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity -17% (FY2009) → 14% (FY2025) · on assets 11.1%

Balance sheetLiabilitiesEquity

FY2025: $40.56B assets · $9.30B liabilities · $31.26B equity

The receipts

REGENERON PHARMACEUTICALS, INC.

REGN · CIK 0000872589

18 fiscal years · 65 SEC filings · every number carries its receipt

Revenue (FY)

$14.34B1.0%

FY2025

Net income (FY)

$4.50B2.1%

FY2025

Free cash flow (FY)

$4.08B11.3%

FY2025

Diluted EPS (FY)

$41.488.2%

FY2025

The story, charted

The shape of the business

FY2008–FY2025 · hover any year for its receipt

Revenue & net incomeRevenueNet income

revenue 60.1× since FY2008 · net margin -33.2% → 31.4%

MarginsNet marginFCF margin

FY2025: net 31.4% · free cash flow 28.4% of revenue

Cash engineOperating cash flowFree cash flow

FY2025: $4.98B operating cash − $898.4M capex = $4.08B free cash flow

Returns on capitalReturn on equityReturn on assets

return on equity -17% (FY2009) → 14% (FY2025) · on assets 11.1%

Balance sheetLiabilitiesEquity

FY2025: $40.56B assets · $9.30B liabilities · $31.26B equity

The receipts